Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)
Condition: Postprandial Hypoglycemia Intervention: Drug: Canagliflozin 300 MG Oral Tablet Sponsor: Hospital Universitari Vall d'Hebron Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2021 Category: Research Source Type: clinical trials
The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT)
DiscussionThe reason that we use metformin as an active control is to avoid yielding differences in glycemic control between the luseogliflozin and control groups. Besides, metformin is considered to have a neutral effect on bone. This trial should reveal the effect of luseogliflozin on bone metabolism in older patients with T2DM.Trial registrationThe study was registered with the University Hospital Medical Information Network (UMIN000036202) on 1 April 2019 and with the Japan Registry of Clinicla Trials (jRCTs071180061) on 14 March 2019. (Source: Trials)
Source: Trials - May 4, 2020 Category: Research Source Type: clinical trials
A Study of Canagliflozin + Metformin Hydrochloride Immediate Release (IR) Fixed-Dose Combination as an Adjunct to Diet and Exercise to Improve Glycemic Control in Indian Adult Participants With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus Intervention: Drug: Canagliflozin + Metformin hydrochloride (Fixed Dose Combination) Sponsor: Johnson & Johnson Private Limited Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 2, 2020 Category: Research Source Type: clinical trials
